6-amino-1-hydroxyhexane-1,1-diphosphonate and beta-Thalassemia

6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with beta-Thalassemia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bhardwaj, A; Sinha, NK; Swe, KMM	1
Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM	1
Celli, M; D'Eufemia, P; Finocchiaro, R; Iacobini, M; Raccio, I; Smacchia, P; Tetti, M; Zambrano, A	1
Baldini, M; Borgna Pignatti, C; Cappellini, MD; D'Ascola, DG; Filosa, A; Forni, GL; Giusti, A; Iolascon, G; Nobili, B; Palummeri, E; Perrotta, S; Pinto, V; Pitrolo, L; Quarta, G; Rigano, P; Rosa, A	1

Reviews

2 review(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and beta-Thalassemia

Article	Year
Treatment for osteoporosis in people with beta-thalassaemia. The Cochrane database of systematic reviews, 2023, 05-09, Volume: 5 Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Pamidronate	2023
Treatment for osteoporosis in people with ß-thalassaemia. The Cochrane database of systematic reviews, 2016, Mar-10, Volume: 3 Topics: Adolescent; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Child; Clodronic Acid; Diphosphonates; Female; Femur Neck; Humans; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Zinc Sulfate	2016

Trials

2 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and beta-Thalassemia

Article	Year
Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:4 Topics: Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Male; Osteoporosis; Taurine; Time Factors; Young Adult	2010
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. British journal of haematology, 2012, Volume: 158, Issue:2 Topics: Adolescent; Adult; Alkaline Phosphatase; Back Pain; beta-Thalassemia; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Quality of Life; Treatment Outcome; Young Adult	2012

Article

Year

Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:4

Topics: Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Male; Osteoporosis; Taurine; Time Factors; Young Adult

2010

Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.

British journal of haematology, 2012, Volume: 158, Issue:2

Topics: Adolescent; Adult; Alkaline Phosphatase; Back Pain; beta-Thalassemia; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Quality of Life; Treatment Outcome; Young Adult

2012